Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

Blueprint specializes in systemic mastocytosis, a rare immunological disease, and other Kit-driven diseases. With this ...

The recent “Most Favoured Nation” executive order is creating an overhang on biotech stocks and opportunities for selective ...

Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s ...

SNY, BMY, REGN and others ramp up 2025 dealmaking as pharma/biotech giants chase innovation across key growth areas.

The UK Financial Conduct Authority teams up with Nvidia to launch a powerful AI sandbox, giving financial firms access to ...

Oil prices dipped slightly on weak Chinese economic data, but broader market sentiment remains buoyant ahead of crucial ...

Wall Street gains as S&P 500 surpasses 6,000; key healthcare stock movers revealed. Explore top deals, trends, and regulatory updates in the sector.

MarioGuti Most major stock indexes across the globe ended the week higher, as renewed optimism around US-China trade talks ...

Sanofi announced it is punting more than $9 billion to acquire Blueprint Medicines and its Ayvakit, BLU-808 and immunology ...

With the S&P 500 up 23% in 2024, getting richer was easier than usual. The number of North Americans with at least $1 million ...

Sanofi (SNY) has its hands full—in the best way possible—after announcing its $9.5 billion acquisition of Blueprint Medicines. This marks the French pharma giant’s fourth major strategic acquisition ...